The company is banking on its respiratory vaccine candidates to help offset the expected steep fall in revenue from its hugely successful COVID-19 vaccine

Related Keywords

Boston , Massachusetts , United States , Raffael Nachbagauer , Mani Foroohar , Hartaj Singh , Moderna Inc , Company , Moderna , Vaccine , Trial , Flu , Response , Rsv , Success , Reuters ,